HID Global, DellTM combine technologies to meet needs of healthcare sector
Worldwide leader in security identify solutions namely HID Global and DellTM have announced that they have combined their technologies to meet the growing needs of the healthcare industry.
HID Global has provided OMNIKEY® 5321 readers for use with Dell’s mobile clinical computing solution, that offers greater security through a single authentication, fast and automatic, made with their own ID badge.
The solution allows the healthcare providers to have secure access to all the authorized data and applications without the need to memorize different login IDs and passwords to hospital systems or external solutions.
The unique signature and authentication features, Dell’s mobile clinical computing solution consisting of pillars including cross platform virtualization and mobility equipment, providing healthcare companies more efficiency, productivity and complete data security. The purpose of mobile clinical computing solution is to bring mobility to the hospital, save time, improve the quality of patient care, and increase hospital’s operational productivity up to 25%.
Gustavo Gassmann, Director of Sales at HID Global in Brazil said, “The Company’s solution is ideal for hospitals with professionals who need to share the same computer and system. The two factor authentication is always used for employee access, the identification card that can also be used for physical access, and a password. Besides, the ease of use of the technology, security is guaranteed for the multiple users who share the same medicine.”
With a dual interface, HID Global’s OMNIKEY 5321 reader is for external use via USB and supports 13.56 MHz contactless iClass® and MIFARE®cards that follow ISO 14443 A/B and ISO 15693 standards.
The reader allows the users to experience the convenience, speed and security of contactless technology for different applications including login Windows®, networks, web sites and applications for the secure storage of user names, passwords and personal information.
HID Global is a good source for innovative products, services, solutions and know-how related to creating, use and management of secure identities for many customers around the world.
NHS opens 8 clinical trial sites to assess cancer treatment
The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy.
The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment. They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities.
Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.
OncoHost, an oncology startup, will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®.
“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.
“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient."
"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”
Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.